title: Kinetic and pharmacological properties of human brain Na(+)/H(+) exchanger isoform 5 stably expressed in Chinese hamster ovary cells.
abstract: The recently cloned Na(+)/H(+) exchanger isoform 5 (NHE5) is expressed predominantly in brain, yet little is known about its functional properties. To facilitate its characterization, a full-length cDNA encoding human NHE5 was stably transfected into NHE-deficient Chinese hamster ovary AP-1 cells. Pharmacological analyses revealed that H(+)(i)-activated (22)Na(+) influx mediated by NHE5 was inhibited by several classes of drugs (amiloride compounds, 3-methylsulfonyl-4-piperidinobenzoyl guanidine methanesulfonate, cimetidine, and harmaline) at half-maximal concentrations that were intermediate to those determined for the high affinity NHE1 and the low affinity NHE3 isoforms, but closer to the latter. Kinetic analyses showed that the extracellular Na(+) dependence of NHE5 activity followed a simple hyperbolic relationship with an apparent affinity constant (K(Na)) of 18.6 +/- 1.6 mM. By contrast to other NHE isoforms, NHE5 also exhibited a first-order dependence on the intracellular H(+) concentration, achieving half-maximal activation at pH 6.43 +/- 0.08. Extracellular monovalent cations, such as H(+) and Li(+), but not K(+), acted as effective competitive inhibitors of (22)Na(+) influx by NHE5. In addition, the transport activity of NHE5 was highly dependent on cellular ATP levels. Overall, these functional features distinguish NHE5 from other family members and closely resemble those of an amiloride-resistant NHE isoform identified in hippocampal neurons.
authors.affiliation: Department of Physiology, McGill University, Montréal, Québec H3G 1Y6, Canada.
authors.forename: E Z
authors.initials: EZ
authors.lastname: Szabó
authors.forename: M
authors.initials: M
authors.lastname: Numata
authors.forename: G E
authors.initials: GE
authors.lastname: Shull
authors.forename: J
authors.initials: J
authors.lastname: Orlowski
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000584:Amiloride / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000378:metabolism*; D016466:CHO Cells; D002927:Cimetidine / Q000494:pharmacology; D006224:Cricetinae; D006146:Guanidines / Q000494:pharmacology; D006246:Harmaline / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008094:Lithium / Q000494:pharmacology; D008565:Membrane Proteins; D011188:Potassium / Q000494:pharmacology; D020033:Protein Isoforms; D012979:Sodium Radioisotopes; D000074083:Sodium-Hydrogen Exchanger 3; D017923:Sodium-Hydrogen Exchangers / Q000235:genetics / Q000378:metabolism*; D013450:Sulfones / Q000494:pharmacology; D014162:Transfection
chemical_list: D006146:Guanidines; D008565:Membrane Proteins; D020033:Protein Isoforms; C000613385:SLC9A3 protein, human; D012979:Sodium Radioisotopes; D000074083:Sodium-Hydrogen Exchanger 3; D017923:Sodium-Hydrogen Exchangers; D013450:Sulfones; C069139:growth factor-activatable Na-H exchanger NHE-1; C117561:sodium-hydrogen exchanger 5; C074107:3-methylsulfonyl-4-piperidinobenzoyl guanidine; D000584:Amiloride; D002927:Cimetidine; D000255:Adenosine Triphosphate; D008094:Lithium; D006246:Harmaline; D011188:Potassium; C039614:ethylisopropylamiloride